Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

DZNE image

News from DZNE

All of today’s top news stories from DZNE. Get the full analysis behind how media bias impacts breaking news.

Overall, we’ve indexed 3 stories from DZNE over the past 3 months.

DZNE’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

DZNE’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about DZNE

Where is DZNE located?DZNE's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top DZNE News

Award for Lars Lannfelt, Pioneer of Alzheimer's Drug "Lecanemab"

Uppsala · Uppsala

Award for Lars Lannfelt, Pioneer of Alzheimer's Drug "Lecanemab"

Scientists from Sweden are awarded "Hartwig Piepenbrock DZNE Prize" Bonn/Osnabrück, Stockholm (Sweden), June 26, 2025. The "Hartwig Piepenbrock DZNE Prize", endowed with 60,000 euros, will be awarded this year to Swedish medical scientist Lars Lannfelt for his pioneering contributions to the understanding of Alzheimer's disease and the development of the drug "Lecanemab". This is used for the treatment of Alzheimer's, the most common dementia di…Read Article

You've scrolled to the bottom of the feed, there are no more stories.